Heart failure & cardiomyopathiesRandomised controlled trial
Effects of Geranylgeranylacetone on Diastolic and Microvascular Function in Patients with Heart Failure with a Preserved Ejection Fraction: A Phase 2, Randomized, Placebo-Controlled, Crossover Trial
- Randomised controlled trial
- phase 2
- double-blind
- placebo-controlled
- crossover
- per-protocol analysis
Authors' conclusion
Geranylgeranylacetone, a drug that showed promising effects on myocardial relaxation and endothelial function in preclinical studies, had no effects on diastolic function, endothelial function and exercise capacity in patients with HFpEF.
Study context
- Population
- Patients with heart failure with preserved ejection fraction (HFpEF)39 in per-protocol analysis
- Participants
- 43 patients
- Comparison
- GGA vs placebo
- Primary endpoint
- Dual primary: diastolic function (E/e') and reactive hyperaemia index (RHI)
Primary result
As reported in the abstract
Dual primary: E/e' and RHI
No significant difference in E/e'
−0.24 [−0.90-0.41], p = 0.46
No significant difference in reactive hyperaemia index (RHI)
−0.02 [−0.36-0.33], p = 0.92
Secondary outcomes
Renal haemodynamics (BSA-adjusted ERPF and RBF)
- Decrease in BSA-adjusted ERPF
- −29.62[−57.52;1.71], p = 0.038
- Decrease in BSA-adjusted RBF
- −50.20 [−95.80; −4.61], p = 0.032
Original publication
Effects of Geranylgeranylacetone on Diastolic and Microvascular Function in Patients with Heart Failure with a Preserved Ejection Fraction: A Phase 2, Randomized, Placebo-Controlled, Crossover Trial. Eur J Heart Fail. Published 28 July 2025. doi:10.1002/ejhf.3711
Summarised from the published abstract; every number is checked against it